{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:21:16Z","timestamp":1793042476802,"version":"4.5.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Aims:<\/jats:title>\n                    <jats:p>The prevalence of NAFLD is increasing globally and on a path to becoming the most frequent cause of chronic liver disease. Strategies for the prevention and treatment of NAFLD are urgently needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Approach and Results:<\/jats:title>\n                    <jats:p>A 6\u2010month prospective, randomized, double\u2010blind, placebo\u2010controlled clinical trial was conducted to assess the efficacy of daily NRPT (commercially known as Basis, a combination of nicotinamide riboside and pterostilbene) supplementation in 111 adults with NAFLD. The study consisted of three arms: placebo, recommended daily dose of NRPT (NRPT 1\u00d7), and a double dose of NRPT (NRPT 2\u00d7). NRPT appeared safe and well tolerated. At the end of the study, no significant change was seen in the primary endpoint of hepatic fat fraction with respect to placebo. However, among prespecified secondary outcomes, a time\u2010dependent decrease in the circulating levels of the liver enzymes alanine aminotransferase (ALT) and gamma\u2010glutamyltransferase (GGT) was observed in the NRPT 1\u00d7 group, and this decrease was significant with respect to placebo. Furthermore, a significant decrease in the circulating levels of the toxic lipid ceramide 14:0 was also observed in the NRPT 1\u00d7 group versus placebo, and this decrease was associated with a decrease in ALT in individuals of this group. A dose\u2010dependent effect was not observed with respect to ALT, GGT, or ceramide 14:0 in the NRPT 2\u00d7 group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This study demonstrates that NRPT at the recommended dose is safe and may hold promise in lowering markers of hepatic inflammation in patients with NAFLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.32778","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T06:09:29Z","timestamp":1662703769000},"page":"863-877","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":48,"title":["Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double\u2010blind, placebo\u2010controlled clinical trial"],"prefix":"10.1097","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2191-5878","authenticated-orcid":false,"given":"Ryan W.","family":"Dellinger","sequence":"first","affiliation":[{"name":"Elysium Health New York, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly E.","family":"Holmes","sequence":"additional","affiliation":[{"name":"Elysium Health New York, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Hu\u2010Seliger","sequence":"additional","affiliation":[{"name":"Elysium Health New York, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney W.","family":"Butt","sequence":"additional","affiliation":[{"name":"Nutrasource, Guelph, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Pinnacle Clinical Research, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariush","family":"Mozaffarian","sequence":"additional","affiliation":[{"name":"Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Chen","sequence":"additional","affiliation":[{"name":"Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts, USA"},{"name":"Biofortis Research, Addison, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Guarente","sequence":"additional","affiliation":[{"name":"Elysium Health New York, New York, New York, USA"},{"name":"Department of Biology, MIT, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"key":"hep32778-bib-0001-20250824","article-title":"Natural history of NAFLD","volume":"10","year":"2021","journal-title":"J Clin Med"},{"key":"hep32778-bib-0002-20250824","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1113\/JP280908","article-title":"NAD+ and NAFLD\u2014caution, causality and careful optimism","volume":"600","year":"2022","journal-title":"J Physiol"},{"key":"hep32778-bib-0003-20250824","article-title":"Too much of a good thing? An evolutionary theory to explain the role of ceramides in NAFLD","volume":"11","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"hep32778-bib-0004-20250824","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","year":"2018","journal-title":"Hepatology"},{"key":"hep32778-bib-0005-20250824","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2337\/dc17-1318","article-title":"Specific hepatic sphingolipids relate to insulin resistance, oxidative stress, and inflammation in nonalcoholic steatohepatitis","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"hep32778-bib-0006-20250824","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.tcb.2014.04.002","article-title":"NAD+ and sirtuins in aging and disease","volume":"24","year":"2014","journal-title":"Trends Cell Biol"},{"key":"hep32778-bib-0007-20250824","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nature02583","article-title":"Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR\u2010gamma","volume":"429","year":"2004","journal-title":"Nature"},{"key":"hep32778-bib-0008-20250824","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2006.11.013","article-title":"Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC\u20101alpha","volume":"127","year":"2006","journal-title":"Cell"},{"key":"hep32778-bib-0009-20250824","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.molcel.2011.07.019","article-title":"SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome","volume":"44","year":"2011","journal-title":"Mol Cell"},{"key":"hep32778-bib-0010-20250824","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nature05486","article-title":"Sirtuins as potential targets for metabolic syndrome","volume":"444","year":"2006","journal-title":"Nature"},{"key":"hep32778-bib-0011-20250824","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1096\/fj.10-173492","article-title":"Hepatic overexpression of SIRT1 in mice attenuates endoplasmic reticulum stress and insulin resistance in the liver","volume":"25","year":"2011","journal-title":"FASEB J"},{"key":"hep32778-bib-0012-20250824","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1053\/j.gastro.2013.10.059","article-title":"Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21","volume":"146","year":"2014","journal-title":"Gastroenterology"},{"key":"hep32778-bib-0013-20250824","doi-asserted-by":"crossref","first-page":"852","DOI":"10.7150\/ijbs.19370","article-title":"Emerging roles of SIRT1 in fatty liver diseases","volume":"13","year":"2017","journal-title":"Int J Biol Sci"},{"key":"hep32778-bib-0014-20250824","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1172\/JCI41563","article-title":"Sirt1 activation protects the mouse renal medulla from oxidative injury","volume":"120","year":"2010","journal-title":"J Clin Invest"},{"key":"hep32778-bib-0015-20250824","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.cmet.2012.04.022","article-title":"The NAD+ precursor nicotinamide riboside enhances oxidative metabolism and protects against high\u2010fat diet\u2013induced obesity","volume":"15","year":"2012","journal-title":"Cell Metab"},{"key":"hep32778-bib-0016-20250824","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/hep.28245","article-title":"Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice","volume":"63","year":"2016","journal-title":"Hepatology"},{"key":"hep32778-bib-0017-20250824","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.tips.2013.12.004","article-title":"Small molecule SIRT1 activators for the treatment of aging and age\u2010related diseases","volume":"35","year":"2014","journal-title":"Trends Pharmacol Sci"},{"key":"hep32778-bib-0018-20250824","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s10495-016-1258-x","article-title":"SIRT1 activation by pterostilbene attenuates the skeletal muscle oxidative stress injury and mitochondrial dysfunction induced by ischemia reperfusion injury","volume":"21","year":"2016","journal-title":"Apoptosis"},{"key":"hep32778-bib-0019-20250824","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejphar.2016.02.052","article-title":"Restoration of sirt1 function by pterostilbene attenuates hypoxia\u2010reoxygenation injury in cardiomyocytes","volume":"776","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"hep32778-bib-0020-20250824","article-title":"Recent advances in synthesis, bioactivity, and pharmacokinetics of pterostilbene, an important analog of resveratrol","volume":"25","year":"2020","journal-title":"Molecules"},{"key":"hep32778-bib-0021-20250824","article-title":"Pterostilbene reduces liver steatosis and modifies hepatic fatty acid profile in obese rats","volume":"11","year":"2019","journal-title":"Nutrients"},{"key":"hep32778-bib-0022-20250824","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s12035-020-02188-7","article-title":"Nicotinamide riboside and pterostilbene cooperatively delay motor neuron failure in ALS SOD1(G93A) Mice","volume":"58","year":"2021","journal-title":"Mol Neurobiol"},{"key":"hep32778-bib-0023-20250824","article-title":"Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double\u2010blind, placebo\u2010controlled study","volume":"3","year":"2017","journal-title":"NPJ Aging Mech Dis"},{"key":"hep32778-bib-0024-20250824","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1148\/radiol.2511080666","article-title":"Nonalcoholic fatty liver disease: diagnostic and fat\u2010grading accuracy of low\u2010flip\u2010angle multiecho gradient\u2010recalled\u2010echo MR imaging at 1.5 T","volume":"251","year":"2009","journal-title":"Radiology"},{"key":"hep32778-bib-0025-20250824","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/jmri.23928","article-title":"Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging","volume":"37","year":"2013","journal-title":"J Magn Reson Imaging"},{"key":"hep32778-bib-0026-20250824","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1148\/radiol.10100659","article-title":"Estimation of hepatic proton\u2010density fat fraction by using MR imaging at 3.0 T","volume":"258","year":"2011","journal-title":"Radiology"},{"key":"hep32778-bib-0027-20250824","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/ajcn\/nqy132","article-title":"A randomized placebo\u2010controlled clinical trial of nicotinamide riboside in obese men: safety, insulin\u2010sensitivity, and lipid\u2010mobilizing effects","volume":"108","year":"2018","journal-title":"Am J Clin Nutr"},{"key":"hep32778-bib-0028-20250824","article-title":"The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"hep32778-bib-0029-20250824","article-title":"Roles of ceramides in non\u2010alcoholic fatty liver disease","volume":"10","year":"2021","journal-title":"J Clin Med"},{"key":"hep32778-bib-0030-20250824","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2018.09.021","article-title":"Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis","volume":"156","year":"2019","journal-title":"Gastroenterology"},{"key":"hep32778-bib-0031-20250824","article-title":"Comparative effects of pterostilbene and its parent compound resveratrol on oxidative stress and inflammation in steatohepatitis induced by high\u2010fat high\u2010fructose feeding","volume":"9","year":"2020","journal-title":"Antioxidants (Basel)"},{"key":"hep32778-bib-0032-20250824","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41569-021-00536-1","article-title":"Ceramides and other sphingolipids as drivers of cardiovascular disease","volume":"18","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"hep32778-bib-0033-20250824","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1172\/JCI131838","article-title":"Machine learning reveals serum sphingolipids as cholesterol\u2010independent biomarkers of coronary artery disease","volume":"130","year":"2020","journal-title":"J Clin Invest"},{"key":"hep32778-bib-0034-20250824","article-title":"Association between plasmatic ceramides profile and AST\/ALT ratio: C14:0 ceramide as predictor of hepatic steatosis in adolescents independently of obesity","volume":"2017","year":"2017","journal-title":"Can J Gastroenterol Hepatol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.32778","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.32778","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.32778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T22:05:47Z","timestamp":1756073147000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.32778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.32778","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,22]]},"assertion":[{"value":"2022-04-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}